TransMedics Group, Inc.
TransMedics Group, Inc. (NASDAQ: TMDX) operates as a medical technology company focused on transforming organ transplant therapy through innovative preservation and procurement solutions. The company's website is www.transmedics.com. From the company’s description.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What TransMedics Group, Inc. does
In the company’s own words
TransMedics Group, Inc. (NASDAQ: TMDX) operates as a medical technology company focused on transforming organ transplant therapy through innovative preservation and procurement solutions. The company's website is www.transmedics.com.
The company's core business centers on the Organ Care System (OCS), a portable, multi-organ warm perfusion platform that represents the only FDA-approved device of its kind on the market. The OCS addresses fundamental limitations of traditional cold storage organ preservation by maintaining donor organs in a living, functioning state outside the human body through warm, oxygenated, nutrient-enriched blood perfusion. This enables organ optimization, viability assessment, and significantly reduces ischemic injury compared to conventional methods. TransMedics has developed three OCS products for heart, lung, and liver transplantation, all approved for organs from both brain-dead and circulatory-dead donors. The company is also developing OCS Kidney leveraging next-generation Gen-3 technology.
Complementing its device offerings, TransMedics operates the National OCS Program (NOP), a comprehensive turnkey solution providing outsourced organ procurement, OCS perfusion management, and transplant logistics services to transplant centers nationwide. The NOP includes dedicated aviation transportation through a fleet of 22 owned fixed-wing aircraft acquired following the August 2023 acquisition of Summit Aviation, enabling end-to-end organ delivery services.
As of December 31, 2025, the company employed 898 full-time staff members worldwide, with primary operations in Andover, Massachusetts, supplemented by facilities in Somerville, Massachusetts, Dallas, Texas, and distributed teams supporting NOP operations across the United States. The company maintains additional distribution, commercial, and research and development operations in Europe, including facilities in Mirandola, Italy.
TransMedics generated $605.5 million in total revenue during 2025, reflecting strong year-over-year growth. The business model emphasizes recurring revenue derived primarily from sales of single-use, organ-specific disposable sets required for each OCS transplant procedure and services provided through the NOP. The company's competitive advantages include its multi-organ platform capability, established clinical relationships with leading transplant centers, substantial clinical evidence from large-scale trials, and integrated logistics infrastructure supporting efficient organ procurement and delivery.
Company details
- Sector
- Healthcare
- Industry
- Electromedical Apparatus
- Headquarters
- ANDOVER, MA
- Fiscal year end
- December
- CIK
- 1756262
- SIC
- 3845
Financial performance, year by year
Fiscal 2019–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns TransMedics Group, Inc. — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Largest fund holders · TransMedics Group, Inc.’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
TransMedics Group, Inc.’s bonds, as funds hold them
Funds report holding 1 issues of TransMedics Group, Inc.’s debt, $35.26M at market value — what funds hold, not the company’s total debt. Weighted-average coupon 1.50%, maturing 2028 to 2028.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do TransMedics Group, Inc. and its peers compare on margins and cash generation over ten years?”
- “Where did five years of TransMedics Group, Inc.'s earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in TransMedics Group, Inc.'s last four quarterly filings that the numbers alone won't show?”